Since our pioneering work on penicillin in the 1940s, Pfizer has been actively engaged in the development of innovative medicines, and creation of tools, policies and educational programs to address the evolving needs of patients and physicians in the area of infectious diseases.
Today, Pfizer is a leading global provider of anti-infective medicines, offering patients access to a diverse portfolio of products across a wide number of countries, including low- and middle-income countries.
Our current portfolio of anti-infectives includes therapies that help address the unmet medical needs, such as the treatment of Gram-negative and Gram-positive bacterial infections, viral infections and invasive fungal infections. Many of these therapies are administered in a hospital setting to patients living with serious infections that are difficult to treat.
We are also committed to R&D to support the development of medicines to both treat and help prevent infections caused by resistant pathogens. We continue to evaluate opportunities and partnerships to expand our R&D pipeline to ensure we address the evolving medical needs of people and physicians in this important area of infectious disease.